Purpose of Study
Evaluate the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF40-60 (HF with LVEF 40-60%).
Trial Status
Enrolling
Eligibility Criteria
LVEF ≥40% and <60% with symptomatic heart failure
Duration of Participation
Approximately 5-6 years
Contact Name: Cayla Garner, RN
Contact Phone: 515-235-5089
Contact Email: cayla.garner@mercyoneiowa.org